The Association Between Different Markers With Development of Maternal and Neonatal Complications in Women With Severe Preeclampsia

NCT ID: NCT07125599

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

284 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-02

Study Completion Date

2025-05-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

pregnant women diagnosed with severe preeclampsia were subjected to • Full history taking including a detailed history of the hypertension state during the current pregnancy (onset, course, current medication, and whether the blood pressure is controlled or not).gravidity , parity mode of delivery any medical disorders, the presence of headache ,blurring of vision and epigastric pain.

* Complete physical examination: general (including BMI \& blood pressure measurement) and obstetric examinations.
* Routine obstetric ultrasound and Doppler indices Including umbilical artery Doppler (RI).
* Laboratory investigations :

1\. Complete blood count (CBC). 2 albuminuria will be detected by dipstick kits . 3. Liver enzymes \& kidney function. 4.PT,PC,INR.
* Pelvic-Abdominal ultrasound to assess the presence of ascites Ultrasound examination will be performed by a consultant obstetrician to detect free fluid in the peritoneal cavity, especially at hepato-renal pouch, sub-splenic area, or para-colic gutters.

The presence of ascites will be further confirmed at the time of delivery.

3-All labours will be attended by an expert neonatologist and the following will be recorded:

* APGAR score at (1 min).
* The further need for neonatal intensive care unit (NICU) admission.
* Perinatal death

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

pregnant women diagnosed with severe preeclampsia were subjected to • Full history taking including a detailed history of the hypertension state during the current pregnancy (onset, course, current medication, and whether the blood pressure is controlled or not).gravidity , parity mode of delivery any medical disorders, the presence of headache ,blurring of vision and epigastric pain.

* Complete physical examination: general (including BMI \& blood pressure measurement) and obstetric examinations.
* Routine obstetric ultrasound and Doppler indices Including umbilical artery Doppler (RI).
* Laboratory investigations :

1\. Complete blood count (CBC). 2 albuminuria will be detected by dipstick kits . 3. Liver enzymes \& kidney function. 4.PT,PC,INR.
* Pelvic-Abdominal ultrasound to assess the presence of ascites Ultrasound examination will be performed by a consultant obstetrician to detect free fluid in the peritoneal cavity, especially at hepato-renal pouch, sub-splenic area, or para-colic gutters.

The presence of ascites will be further confirmed at the time of delivery.

3-All labours will be attended by an expert neonatologist and the following will be recorded:

* APGAR score at (1 min).
* The further need for neonatal intensive care unit (NICU) admission.
* Perinatal death

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Maternal age from 18 to 40 years.
2. Gestational age (28\_38) weeks, confirmed by the first day of the last menstrual period or first trimesteric ultrasound
3. All suffering of severe preeclampsia

Exclusion Criteria

1. known liver disease
2. Maternal medical disorders rather than hypertension.
3. Rupture of membrane.
4. Renal disorder.
5. History of illicit drug use.
6. Fetal congenital anomalies.
7. The maternal administration of respiratory depressants within 2 hours from the delivery of the fetus (e. g., opioid analgesic )
8. Associated inflammatory disease or sepsis.
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ahmed M Maged, MD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ahmed Maged, MD

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo university

Cairo, Cairo Governorate, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Cairo university

Identifier Type: OTHER

Identifier Source: secondary_id

366

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.